Insider buying last 90 days
No open-market insider purchases were filed for OPCH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every OPCH insider filing, plotted on the chart in Gekko.Open OPCH in Gekko
NASDAQ: OPCH
Option Care Health (OPCH) Stock Analysis & Forecast
Oct 12 close
$31.10+0.03 (+0.1%)
Gekko Brief
AI summaryOct 12 closeOption Care Health's week has been dominated by news of a proposed sale to an investor group including affiliates of Clayton, Dubilier & Rice and McKesson Corporation, for $32.05 per share in cash. That price has drawn a string of law-firm investigations into the fairness of the deal, including Monteverde & Associates, Kahn Swick & Foti, and SBS Law. Alongside the deal news, UBS downgraded the stock to Neutral from Buy with a $32.05 price target, and Barrington Research moved its rating from Outperform to Market Perform, even as shares logged a seven-day winning streak that lifted the stock 38% and added $1.3 billion in market value.
OPCH closed at $31.10, up 0.1%, with the price sitting above both its 50-day average of $24.39 and 200-day average of $26.42. The GekkoIndex reads 28.1, placing the stock in the Selling zone, down 32 over five days. Despite the run-up, the price remains 30.8% below the Gekko Fair Value of $44.92.
Earnings are due 4 November 2026, 23 days away, falling inside a typical 20-trading-day holding window; the prior quarter beat estimates with adjusted EPS of $0.41 versus $0.37 expected. No insider, Congress or unusual options activity appears in the recent windows. Seasonally, the next 20 trading days have averaged a -3.7% return over 5 years, rising in 2 of those years. Analyst consensus stands at 10 hold, 1 buy, with a $30.39 price target.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Option Care Health price vs fair value
Close $31.10200-day averageGekko Fair Value $44.92
Option Care Health quick facts
- Market cap
- $4.66B
- P/E ratio
- 23.5
- Forward P/E
- 11.2
- EPS, TTM
- $1.32
- Revenue, TTM
- $5.69B
- Profit margin
- 3.7%
- Dividend yield
- —
- Beta
- 0.58
- Volume
- 4.73M avg 7.02M
- 1-year return
- +16.0%
- Typical daily move
- ±3.1%
- Typical 20-day move
- ±5.7%
- 50-day average
- $24.39
- 200-day average
- $26.42
- Next earnings
- Nov 4 before open
- Shares outstanding
- 149.8M
Option Care Health swing-trade checklist
Option Care Health scores 1 supportive, 1 mixed and 3 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive1 mixed3 headwinds
- Trendmixed
Averages disagree
Close $31.10 sits between the 50-day ($24.39) and 200-day ($26.42) averages, or the averages disagree.
See the chart - GekkoIndexheadwind
28.1, Selling
Reading 28.1 is in the Selling zone.
See the GekkoIndex - Fair valuesupportive
30.8% below
Price is 30.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−3.7% on average
From this point in the calendar, the next 20 trading days averaged −3.7% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Option Care Health stock chart and price history
Option Care Health closed at $31.10 on Oct 12, 2026, +16.0% over the past year, inside a 52-week range of $18.01 to $36.80.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +32.5%
- 3 months
- +45.7%
- 6 months
- +7.5%
- 1 year
- +16.0%
The full OPCH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open OPCH in Gekko
Follow Option Care Health through every session
Put OPCH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track OPCH in GekkoFree for 7 days. No credit card required.
About Option Care Health
Option Care Health provides infusion therapy to patients outside of hospital settings, most often in their own homes, across the United States. Its treatments span infection management, heart failure care, and both intravenous and tube-based nutritional support for people dealing with conditions like stroke, cancer, or digestive disease. The company also handles immunoglobulin infusions for immune disorders, therapies for chronic inflammatory conditions such as Crohn's disease, psoriasis, and rheumatoid arthritis, and care for progressive neurological illnesses including ALS and Duchenne muscular dystrophy.
Beyond these core treatments, Option Care Health supports patients with bleeding disorders, high-risk pregnancies, pain management needs, chemotherapy regimens, and respiratory conditions. Nursing services are built into its offerings, giving patients clinical support alongside their infusion care rather than just the treatments themselves.
The company is headquartered in Bannockburn, Illinois, and its shares are listed on the NASDAQ under the ticker OPCH.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- optioncarehealth.com
Option Care Health GekkoIndex: the smart money zone
Option Care Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 28.1, in the Selling zone, down 32 points over five sessions.
28.1Selling
Down 32 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 49 | +0.3% | −1.0% | ||
| Accumulation | 281 | +0.2% | −0.2% | ||
| Neutral | 318 | −0.1% | −0.4% | ||
| Distribution | 31 | +0.5% | +3.0% | ||
| Selling (current zone) | 3 | Too few readings yet | |||
Average OPCH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Selling readings averaged +7.4% over 20 days. Past behaviour doesn’t guarantee future results.
Selling zone: Smart money likely exiting positions. About the five zones →
See every daily GekkoIndex reading plotted over the OPCH price, zone by zone.Track OPCH in Gekko
Is Option Care Health stock overvalued? Gekko Fair Value
Option Care Health trades 30.8% below Gekko Fair Value of $44.92, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Option Care Health shares are worth, recalculated every trading day.
$44.92
Gekko Fair Value, Oct 10, 2026
30.8% Undervalued
At the end of Aug 2026 the price was 11.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open OPCH in Gekko
Option Care Health insider and Congress trading
No open-market insider purchases were filed for Option Care Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in OPCH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for OPCH, plotted on the chart in Gekko.Open OPCH in Gekko
Buybacks
Option Care Health has been buying back its own shares.
- Latest authorization
- $1.00B, Jan 12, 2026
- Bought back, quarter ended Jun 30, 2026
- $153.0M
- As a share of market cap
- 3.28%
- Trailing four quarters
- $328.1M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold OPCH.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Option Care Health earnings: next date and track record
Option Care Health reports on Nov 4, 2026, before the open (23 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 23 days away
- EPS estimate
- $0.49
- Revenue estimate
- $1.48B
5 of 8reports beat the EPS estimate
±9.1%average move across the report
1 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- Option Care Health reported Q2 2026 results with revenue of $1.4 billion (up 2% year-over-year and 7% sequentially), adjusted EBITDA of $117.5 million (up 3% year-over-year and 12% sequentially), adjusted EPS of $0.45 (up $0.04), strong operating cash flow of $184 million, and net debt leverage of 2.1x. Management highlighted stabilization and early growth in the CID/chronic census, continued strength in acute and IG neuro portfolios, progress on commercial realignment and technology/AI deployments to improve productivity, and continued investments in commercial resources and specialty capabilities. They reiterated 2026 headwinds related to the CID portfolio (approximately 600 bps revenue impact and $55 million gross profit headwind) and noted Stelara and related biosimilars would represent less than 1% of 2026 revenue and gross profit. Management expects H2 seasonal strength (historical H2 vs H1 high-single-digit to low-double-digit growth), sequential improvement through the back half of 2026 based on commercial investments, chronic census recovery, and productivity/technology initiatives; they provided no 2027 guidance. Capital allocation: they completed a $150 million buyback in Q2; no additional buybacks were included in current guidance. Management emphasized ongoing advocacy with policymakers for expanded Medicare home infusion coverage but expects limited near-term material impact from the recent CMS proposal given its narrow scope.
- Guidance
- Reiterated full-year 2026 assumptions: year-over-year revenue headwinds ~600 basis points and gross profit headwinds of $55 million due to CID portfolio dynamics; Stelara/biosimilar impact expected to be <1% of 2026 net revenue and gross profit. Q3 guidance (discussed qualitatively) assumes continued high-single-digit acute growth and continued chronic census recovery; management expects sequential improvement into Q3 and Q4 with historical H2 vs H1 high-single-digit to low-double-digit growth. No 2027 guidance provided. Current guidance does not assume any incremental buybacks beyond the $150M executed in Q2.
- Risks flagged
- CID portfolio headwinds (including biosimilar/formulary shifts), uncertainty in ramp timing for rare/orphan product launches and approvals, PBM/formulary/white-bagging dynamics, dependence on payer contracting and site-of-care initiatives, potential variability in variable compensation tied to performance, and limited near-term impact from narrow CMS coverage expansions. These risks could negatively affect revenue, gross profit, and cadence of recovery.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | $0.41 est $0.37 | $1.44B est $1.42B | −0.1% |
| Apr 30, 2026 | $0.40 est $0.41 | $1.35B est $1.39B | −25.5% |
| Feb 24, 2026 | $0.46 est $0.46 | $1.47B est $1.46B | −6.9% |
| Oct 30, 2025 | $0.45 est $0.43 | $1.44B est $1.46B | −9.2% |
| Jul 30, 2025 | $0.41 est $0.38 | $1.42B est $1.40B | −2.6% |
| Apr 29, 2025 | $0.40 est $0.35 | $1.33B est $1.34B | −2.0% |
| Feb 26, 2025 | $0.37 est $0.36 | $1.35B est $1.23B | +1.7% |
| Oct 30, 2024 | $0.31 est $0.31 | $1.28B est $1.27B | −24.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Option Care Health stock forecast and analyst price targets
Analysts’ average 12-month price target for Option Care Health is $30.39, −2.3% from the last close, from 11 firms rating the stock in the last 90 days.
$30.39consensus 12-month target, −2.3% from the last close
Now $31.10Avg $30.39
Low $23High $33
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Morgan Stanley | $32.05 | +3.1% |
| Oct 10 | J.P. Morgan | $33 | +6.1% |
| Oct 9 | UBS | $32.05 | +3.1% |
| Oct 7 | Barrington | — | — |
| Oct 7 | J.P. Morgan | $33 | +6.1% |
−3.7%average move over the next 20 trading days in the last 5 years
±3.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Option Care Health seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Option Care Health averaged −3.7% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.3% | 4 of 5 |
| Next 10 trading days | +4.4% | 5 of 5 |
| Next 15 trading days | −6.0% | 1 of 5 |
| Next 20 trading days | −3.7% | 2 of 5 |
| Next 30 trading days | −4.1% | 2 of 5 |
For scale, OPCH’s typical 20-trading-day move in either direction is about 5.7%.
Option Care Health market cap and key statistics
Option Care Health’s market cap is $4.66B, with a P/E ratio of 23.5 and revenue of $5.69B over the last twelve months.
Valuation
- Market cap
- $4.66B
- P/E ratio
- 23.5
- Forward P/E
- 11.2
- EPS, TTM
- $1.32
- Gekko Fair Value
- $44.92
Trading
- Volume
- 4.73M
- Avg volume, 20 days
- 7.02M
- 52-week high
- $36.80
- 52-week low
- $18.01
- Shares outstanding
- 149.8M
Financials
- Revenue, TTM
- $5.69B
- Profit margin
- 3.7%
- Return on equity
- 16%
- Quarterly earnings growth, YoY
- +12.9%
Risk and income
- Beta
- 0.58
- Typical daily move
- ±3.1%
- Typical 20-day move
- ±5.7%
Option Care Health stock news this week
Coverage of Option Care Health this week reads positive: 6 positive, 1 neutral and 5 negative headlines.
- OPCH Investors Have Opportunity to Join Option Care Health, Inc. Fraud Investigation with SBS LawBusiness Wire, Oct 12
- Monteverde & Associates investigates Option Car...Pluang, Oct 11
- SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Option Care Health, Inc. (NASDAQ: OPCH)PR Newswire, Oct 11
- A 7-Day Winning Streak Has Option Care Health Stock Up 38%Trefis, Oct 10
- Option Care Health Stock: 6 Straight Green Days, Up 38%Trefis, Oct 9
- UBS Downgrades Option Care Health to Neutral From Buy, Price Target is $32.05marketscreener.com, Oct 9
Option Care Health peers
Option Care Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 2.5% below |
| GHGuardant Health | Accumulation | 10.0% below |
| SOLVSolventum | Accumulation | 20.5% below |
| BTSGBrightSpring Health Services | Neutral | 2.8% above |
| EHCEncompass Health | Neutral | 7.3% above |
| DVADaVita | Neutral | 14.6% below |
A peer links to its own page where one exists.
Option Care Health stock FAQ
What is Option Care Health’s market cap?
Option Care Health’s market cap is $4.66B at the Oct 12, 2026 close of $31.10, with 149.8M shares outstanding. The shares trade on a P/E ratio of 23.5.
What is the Option Care Health stock forecast?
The consensus analyst 12-month price target for Option Care Health is $30.39, −2.3% from the last close. Of the 11 firms that rated the stock in the last 90 days, 1 rate it a buy, 10 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Option Care Health stock overvalued or undervalued?
On Gekko’s estimate Option Care Health is undervalued: the Oct 12, 2026 close of $31.10 is 30.8% below Gekko Fair Value of $44.92. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Option Care Health report earnings next?
Option Care Health is expected to report on Nov 4, 2026, before the market opens (23 days away). Analysts expect earnings of $0.49 per share on revenue of $1.48B. Option Care Health beat the earnings estimate in 5 of its last 8 reports, moving 9.1% on average across the report.
What is Option Care Health’s 52-week high and low?
Option Care Health’s 52-week high is $36.80 and its 52-week low is $18.01; it closed at $31.10 on Oct 12, 2026, +16.0% over the past year.
Is Option Care Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (fair value), 1 as mixed (trend) and 3 as headwinds (gekkoindex, earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Option Care Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.